| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Omeprazole D3 targets the gastric H+/K+-ATPase (proton pump) in the parietal cells of the stomach. It binds covalently to the proton pump, irreversibly inhibiting gastric acid secretion. As a labeled analogue, Omeprazole D3 retains the same mechanism of action as the parent compound and is used as a tracer in pharmacokinetic and bioanalytical studies.
|
|---|---|
| ln Vitro |
In vitro activity of Omeprazole D3 is not typically assessed separately from the parent compound, as it is primarily used as an analytical standard. The deuterium labeling does not significantly alter the compound's pharmacological activity, and its proton pump inhibitory effects are expected to be identical to those of unlabeled omeprazole. Omeprazole inhibits gastric acid secretion by blocking the H+/K+-ATPase enzyme.
|
| ln Vivo |
In vivo activity of Omeprazole D3 mirrors that of omeprazole, which is a clinically effective proton pump inhibitor. Omeprazole is used to treat acid-related gastrointestinal disorders by reducing gastric acid secretion. The deuterated analogue is used in pharmacokinetic studies to track the disposition of omeprazole in vivo.
|
| Enzyme Assay |
In vitro enzyme assays for Omeprazole D3 are not typically performed, as the compound is used as an analytical standard rather than as a pharmacological tool. For the parent compound omeprazole, enzyme inhibition assays involve measuring H+/K+-ATPase activity in gastric membrane preparations. The deuterated analogue would be expected to show identical enzyme inhibition properties.
|
| Cell Assay |
In vitro cellular assays for Omeprazole D3 are not typically performed, as the compound is used as an internal standard for LC-MS analysis. The parent compound omeprazole is studied in gastric cell lines or isolated parietal cells to assess acid secretion inhibition. The deuterated analogue serves as a reference for quantifying omeprazole concentrations in cellular samples.
|
| Animal Protocol |
In vivo animal experiments for Omeprazole D3 are typically conducted as part of pharmacokinetic studies. The compound is administered to animals, and blood or tissue samples are collected at various time points. The deuterated compound is used as an internal standard for the quantification of omeprazole levels by LC-MS, enabling accurate measurement of drug concentrations and pharmacokinetic parameters.
|
| ADME/Pharmacokinetics |
Omeprazole D3 is used as an internal standard for the quantification of omeprazole in pharmacokinetic studies by mass spectrometry. The deuterium labeling provides a mass shift that allows the labeled and unlabeled compounds to be distinguished during analysis. The compound has a molecular weight of 348.43 and molecular formula C17H16D3N3O3S. It should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for Omeprazole D3 are not separately reported, as it is a labeled analogue of omeprazole. The safety profile of omeprazole is well established from clinical use, with common adverse effects including headache, nausea, and diarrhea. The deuterated analogue is used in research applications at very low concentrations as an analytical standard, posing minimal toxicity risk.
|
| References |
|
| Additional Infomation |
Omeprazole D3 (H 16868 D3) is a deuterium-labeled analogue of omeprazole with CAS number 922731-01-9, molecular formula C17H16D3N3O3S, and molecular weight 348.43. It is used as an internal standard for the quantification of omeprazole in biological samples by LC-MS. Omeprazole is a proton pump inhibitor used for the treatment of acid-related gastrointestinal disorders. This product is for research use only.
|
| Molecular Formula |
C₁₇H₁₆D₃N₃O₃S
|
|---|---|
| Molecular Weight |
348.43
|
| Exact Mass |
348.133
|
| CAS # |
922731-01-9
|
| Related CAS # |
Omeprazole;73590-58-6;Omeprazole sodium;95510-70-6;Omeprazole-d3-1;934293-92-2;Omeprazole magnesium;95382-33-5;Omeprazole metabolite Omeprazole sulfone (methoxy-d3);1189891-71-1;Omeprazole-13C,d3;1261395-28-1
|
| PubChem CID |
45040154
|
| Appearance |
Light brown to brown solid powder
|
| LogP |
3.765
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])OC1=CC2=C(C=C1)N=C(N2)S(=O)CC3=NC=C(C(=C3C)OC)C
|
| InChi Key |
SUBDBMMJDZJVOS-HPRDVNIFSA-N
|
| InChi Code |
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/i3D3
|
| Chemical Name |
2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-6-(trideuteriomethoxy)-1H-benzimidazole
|
| Synonyms |
Omeprazole D3 H-16868 D3 H 16868 D3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~358.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8700 mL | 14.3501 mL | 28.7002 mL | |
| 5 mM | 0.5740 mL | 2.8700 mL | 5.7400 mL | |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
